Islamabad October 13 2023: Haleon Pakistan Limited will be investing ~USD 10 million in its manufacturing facility at Jamshoro for the production of Panadol base portfolio, including Panadol 500mg and Panadol Extra tablets, according to company filing to the exchange.
The objective is to bring the latest manufacturing technology to Pakistan and enhance the production capacity to 8 billion tablets. This will help the Company to ensure smooth supplies of Pakistan’s largest pharmaceutical / Over-the-Counter medicine to the
consumers and patients in need.
This is in addition to the investment of ~USD 2 million being spent on enhancing manufacturing facility of our flagship brand CaC 1000 Plus to cater to the local needs and export opportunities that the Company is currently working on.
The investment and associated financing have been approved by the Board of Directors of Haleon Pakistan Limited.
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
